Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance. https://www.medrxiv.org/content/10.1101/2023.03.09.23287023
Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance. https://www.medrxiv.org/content/10.1101/2023.03.09.23287023